Fruquintinib · Fruzaqla / Elunate

Small molecule

Also known as HMPL-013

Approvedregulatory verdict

Evidence outlook

Approved: Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Renal Cell Carcinoma · Phase 3 · investigational in the US · under NMPA reviewEndometrial Cancer · Phase 3 · investigational in the US

Also approved (3)
CN
  • Fruquintinib in combination with sintilimab, second-line advanced renal cell carcinoma after prior VEGFR-TKI therapy
Product first approved 2026sec.gov
JP
  • Treatment of unresectable advanced or recurrent colon or rectal cancer that has progressed after cancer chemotherapy
Product first approved 2024PMDA
EU
  • Monotherapy for adults with metastatic colorectal cancer previously treated with available standard therapies who progressed on or are intolerant to trifluridine-tipiracil or regorafenib
Product first approved 2024EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (14)
Advanced Metastatic Colorectal Cancer
NCT07362836 · Fudan University
2026-01-31 – 2030-01-30 · Colorectal Cancer
What this study did
NCT07885384 · West China Hospital
2026-10-08 – 2029-04-28 · Colorectal Cancer
What this study did
Colorectal Cancer
NCT07483684 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2026-03 – 2028-12 · HER2 IHC3+ Advanced Colorectal Cancer
What this study did
NCT07384377 · Shanghai JMT-Bio Inc.
2026-02-06 – 2028-06-15 · HER2-positive Colorectal Cancer
What this study did
NCT06199973 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-03-01 – 2026-06 · Advanced Colorectal Cancer
What this study did
Endometrial Cancer
Renal Cell Carcinoma
NCT07904156 · Sun Yat-sen University
2026-10-21 – 2032-12-30 · Non-Clear Cell Renal Cell Carcinoma (nccRCC)
What this study did
Other / comorbidity
NCT07270991 · Federation Francophone de Cancerologie Digestive
2025-12-15 – 2030-11-30 · Metastatic Oesogastric Adenocarcinoma
What this study did
NCT05914610 · Fujian Medical University
2023-09-01 – 2028-07-30 · Gastric Cancer
What this study did
NCT04164199 · BeOne Medicines
2019-12-19 – 2026-05-23 · Advanced Malignancies
What this study did
NCT03223376 · Hutchison Medipharma Limited
2017-10-18 – 2022-09-09 · Advanced Gastric Cancer
What this study did
Phase 2/3 (4)
Colorectal Cancer
NCT06441565 · Sun Yat-sen University
2024-05-24 – 2029-12-30 · Colorectal Cancer
What this study did
Renal Cell Carcinoma
Other / comorbidity
NCT06443671 · Peking University Cancer Hospital & Institute
2024-06-01 – 2028-06-01 · Rectal Cancer
What this study did
Phase 2 (105)
Advanced Metastatic Colorectal Cancer
NCT07130903 · Barbara Ann Karmanos Cancer Institute
2025-09-10 – 2030-04-17 · Metastatic Colorectal Adenocarcinoma
What this study did
NCT06856837 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-10-27 – 2029-12-31 · Metastatic Colorectal Cancer
What this study did
NCT07286695 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2029-12-31 · Metastatic Colorectal Cancer (CRC), Colorectal Cancer
What this study did
NCT07042685 · The Methodist Hospital Research Institute
2026-01-27 – 2029-12 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT07724223 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-01-16 – 2029-01-31 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT06992258 · Criterium, Inc.
2025-10-27 – 2028-12-31 · Colorectal Cancer
What this study did
NCT07150403 · Federation Francophone de Cancerologie Digestive
2025-12-31 – 2028-10-31 · Metastatic Colorectal Carcinoma (mCRC)
What this study did
NCT07622550 · Jiangsu Cancer Institute & Hospital
2026-06-15 – 2028-08-15 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT07051785 · Liu Huang
2025-07-07 – 2028-07-06 · Colorectal Cancer (CRC)
What this study did
NCT07896096 · Renmin Hospital of Wuhan University
2026-04-14 – 2028-06-30 · Refractory Metastatic Colorectal Cancer
What this study did
NCT07261709 · Sun Yat-sen University
2025-12-01 – 2028-03-30 · Refractory Metastatic Colorectal Cancer
What this study did
NCT07257653 · Zhejiang University
2025-10-21 – 2027-12-31 · Colorectal Neoplasms, RAS, BRAF, Cetuximabβ, Fruquintinib
What this study did
NCT07510932 · Korea University Anam Hospital
2026-05-01 – 2027-09-01 · Colon Cancer
What this study did
NCT07011576 · SCRI Development Innovations, LLC
2025-09-29 – 2027-06 · Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
What this study did
NCT06255379 · Guangzhou University of Traditional Chinese Medicine
2024-05-06 – 2027-03-21 · Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer
What this study did
NCT06746545 · Fujian Cancer Hospital
2025-02-01 – 2027-02-01 · Colorectal Cancer
What this study did
NCT05771181 · Fudan University
2023-03-01 – 2027-02 · Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma
What this study did
NCT06979908 · The First Hospital of Jilin University
2025-01-22 – 2027-01-22 · Metastatic Colorectal Cancer
What this study did
NCT05747716 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-02-28 – 2026-12-31 · Metastatic Colorectal Cancer
What this study did
NCT06685276 · Dai, Guanghai
2024-08-16 – 2026-12 · Colorectal Cancer Metastatic
What this study did
NCT06148402 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-08 – 2026-06-30 · Unresectable/Metastatic Colorectal Cancer
What this study did
NCT05634590 · Fudan University
2022-12 – 2025-12 · Metastatic Colorectal Cancer
What this study did
NCT05659290 · Nanfang Hospital, Southern Medical University
2023-01 – 2025-12 · Metastatic Colorectal Cancer
What this study did
NCT06543836 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-12-01 – 2025-11-30 · Metastatic Colorectal Cancer
What this study did
NCT05555901 · Fudan University
2023-06-18 – 2025-09 · Metastatic Colorectal Cancer
What this study did
NCT05690035 · Sun Yat-sen University
2025-07 – 2025-07 · Metastatic Colorectal Cancer, mCRC
What this study did
NCT05451719 · Fudan University
2022-07 – 2025-07 · Colorectal Cancer, Colorectal Cancer Stage IV
What this study did
NCT05447715 · Weijian Guo
2022-08-31 – 2025-01-31 · Metastatic Colorectal Cancer
What this study did
NCT04296019 · Shanghai Zhongshan Hospital
2021-02-01 – 2025-01-01 · Colo-rectal Cancer
What this study did
NCT05842525 · Hunan Cancer Hospital
2023-10-01 – 2024-12-30 · Colorectal Cancer
What this study did
NCT05004441 · Zhou Fuxiang
2021-07-30 – 2024-11-30 · Metastatic Colorectal Cancer
What this study did
NCT05004831 · Sun Yat-sen University
2022-03-11 – 2024-09 · Metastatic Colorectal Cancer
What this study did
NCT04866108 · Beijing Friendship Hospital
2021-12-08 – 2024-06 · Unresectable Metastatic Colorectal Cancer
What this study did
NCT04924179 · Huazhong University of Science and Technology
2021-06-01 – 2024-06 · Patients With Advanced Metastatic Colorectal Cancer
What this study did
NCT04948034 · Fudan University
2021-08-23 – 2023-12-31 · Metastatic Colorectal Cancer
What this study did
NCT04733963 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-03-01 – 2023-02-01 · Colorectal Cancer
What this study did
NCT04695470 · Aiping Zhou
2020-09-01 – 2022-06-30 · Colorectal Cancer
What this study did
NCT02196688 · Hutchison Medipharma Limited
2014-04 – 2015-11 · Colorectal Cancer
What this study did
Colorectal Cancer
NCT07904130 · West China Hospital
2026-10-09 – 2029-10-01 · Colo-rectal Cancer
What this study did
NCT07515820 · Meng Qiu
2026-04-27 – 2028-04-28 · Colorectal Cancer
What this study did
NCT07136077 · M.D. Anderson Cancer Center
2025-09-18 – 2028-04-01 · Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNA
What this study did
NCT06356597 · Jing-yuan Fang, MD, Ph. D
2024-04-19 – 2027-12-12 · Colorectal Cancer
What this study did
NCT05571644 · Sun Yat-sen University
2023-07-10 – 2027-08-15 · Colorectal Cancer
What this study did
NCT06423937 · Fudan University
2024-05 – 2027-07 · Colorectal Cancer
What this study did
NCT06168786 · Huazhong University of Science and Technology
2023-06-20 – 2027-02-28 · Colorectal Cancer
What this study did
NCT06484153 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-07-22 – 2026-12-30 · To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
What this study did
Phase 1/2 (21)
Advanced Metastatic Colorectal Cancer
NCT06980532 · Liu Huang
2025-04-25 – 2028-12-30 · Metastatic Colorectal Cancer
What this study did
NCT06195670 · Zhejiang Cancer Hospital
2024-01 – 2027-01 · CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
What this study did
NCT05522738 · Chinese PLA General Hospital
2022-08-10 – 2025-12 · Metastatic Colorectal Cancer
What this study did
NCT05016869 · Chinese Academy of Medical Sciences
2022-04-12 – 2024-08 · Metastatic Colorectal Cancer
What this study did
Colorectal Cancer
NCT07591597 · National Cancer Center Hospital East
2026-05 – 2029-05 · Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
What this study did
NCT07621159 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2026-07-15 – 2028-11-01 · Colorectal Cancer Metastatic
What this study did
NCT07491159 · Tianjin Medical University Cancer Institute and Hospital
2023-07-01 – 2026-12-30 · Colorectal Cancer
What this study did
NCT05565417 · Immunitas Therapeutics
2022-11-28 – 2026-01 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
What this study did
NCT01975077 · Hutchison Medipharma Limited
2012-12 – 2014-10 · Colorectal Cancer
What this study did
Endometrial Cancer
NCT04577963 · Hutchmed
2021-08-09 – 2024-06-18 · Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
What this study did
Other / comorbidity
NCT07791758 · Nanjing Leads Biolabs Co.,Ltd
2026-09-28 – 2030-09-04 · Metastatic Colorectal Carcinoma
What this study did
NCT06871527 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-03-01 – 2028-12-31 · Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor, Tislelizumab, GEJ Adenocarcinoma
What this study did
NCT05867420 · AskGene Pharma, Inc.
2023-08-02 – 2028-06-30 · Advanced Solid Tumors
What this study did
NCT06329973 · Henan Cancer Hospital
2024-02-28 – 2028-06-28 · Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05405595 · Adagene Inc
2022-06-15 – 2027-12-31 · Advanced/Metastatic Solid Tumors
What this study did
NCT07334431 · Henan Cancer Hospital
2024-02-22 – 2026-12-31 · Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer, First-line Therapy, Fruquintinib
What this study did
NCT06010212 · The First Affiliated Hospital with Nanjing Medical University
2023-08-25 – 2026-07-01 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05982834 · Fudan University
2023-05-09 – 2025-12 · HER2-positive Gastric Cancer, Immunotherapy
What this study did
NCT05024812 · The First Affiliated Hospital of Zhengzhou University
2022-06-01 – 2025-02 · Metastatic Gastric Cancer
What this study did
NCT03903705 · Hutchmed
2019-04-25 – 2024-12-16 · Advanced Solid Tumor
What this study did
NCT02415023 · Hutchison Medipharma Limited
2014-11-09 – 2017-03-31 · Gastric Cancer
What this study did
Phase 1 (13)
Advanced Metastatic Colorectal Cancer
NCT06347198 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-04-10 – 2025-05-01 · Metastatic Colorectal Cancer
What this study did
NCT05368805 · Hutchmed
2022-03-02 – 2022-04-22 · Metastatic Colorectal Cancer
What this study did
NCT03977090 · Genor Biopharma Co., Ltd.
2019-04-04 – 2021-12 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT05848739 · Sapience Therapeutics
2023-06-05 – 2027-12-31 · Colon Cancer, Metastatic Colon Cancer
What this study did
NCT05216354 · Hutchmed
2022-03-11 – 2023-06-26 · Renal Impairment
What this study did
NCT03251378 · Hutchison Medipharma Limited
2017-12-11 – 2023-03-30 · Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
What this study did
NCT03976856 · Genor Biopharma Co., Ltd.
2019-07-23 – 2022-12 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT05216367 · Hutchmed
2022-03-11 – 2022-10-25 · Hepatic Impairment
What this study did
NCT04645940 · Hutchison Medipharma Limited
2020-09-24 – 2020-11-18 · Drug Interaction, Food-drug Interaction
What this study did
NCT04557397 · Hutchison Medipharma Limited
2020-09-02 – 2020-10-18 · Drug Drug Interaction
What this study did
NCT02689752 · Hutchison Medipharma Limited
2016-07 – 2016-09 · Healthy
What this study did
NCT01955304 · Hutchison Medipharma Limited
2012-06 – 2012-12 · Food Effect of Fruquintinib in Health Subjects
What this study did
NCT01645215 · Hutchison Medipharma Limited
2011-01 – 2012-10 · Tumor
What this study did
Phase 4 (4)
Advanced Metastatic Colorectal Cancer
NCT06118762 · The First Affiliated Hospital of Nanchang University
2023-10-20 – 2026-10-01 · Metastatic Colorectal Cancer
What this study did
Colorectal Cancer
NCT06562543 · Takeda
2025-01-14 – 2027-10-04 · Colorectal Cancer
What this study did
NCT05661357 · Zhongnan Hospital
2023-01-01 – 2025-12-31 · HER2, Colorectal Cancer
What this study did
Metastatic Colorectal Cancer
NCT07446465 · Ye Xu
2026-03-01 – 2027-01-31 · Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
What this study did
Early phase / not applicable (9)
Advanced Metastatic Colorectal Cancer
NCT07124858 · Federation Francophone de Cancerologie Digestive
2026-03-10 – 2031-12-31 · Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological, VEGFR-TKI
What this study did
NCT06613113 · Ningbo Medical Center Lihuili Hospital
2024-08-07 – 2027-07-31 · MSS Metastatic Colorectal Cancer
What this study did
NCT06115733 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2023-12-28 – 2026-12-31 · Colorectal Carcinoma
What this study did
Colorectal Cancer
NCT05928312 · Zhejiang Cancer Hospital
2023-08-28 – 2026-06-01 · Advanced Colorectal Cancer
What this study did
Renal Cell Carcinoma
NCT06317298 · Peking University First Hospital
2024-02-21 – 2025-12-01 · Renal Cell Carcinoma, Clear Cell, Somatic
What this study did
Other / comorbidity
NCT07552402 · Harbin Medical University
2026-06-10 – 2028-12-30 · Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06553781 · Fudan University
2024-09-01 – 2027-09-01 · Malignant Melanoma
What this study did
NCT06158919 · Fudan University
2023-11-20 – 2026-11-20 · Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Advanced Metastatic Colorectal Cancer
NCT07913360 · Genfleet Therapeutics (Shanghai) Inc.
2026-11 – 2030-05 · Colorectal Cancer
What this study did
Colorectal Cancer
NCT06497985 · Chipscreen Biosciences, Ltd.
2024-12-06 – 2028-09-30 · Colorectal Cancer
What this study did
NCT07730489 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-08 – 2027-12 · Colorectal Cancer
What this study did
Phase 2 (1)
Colorectal Cancer
NCT07235293 · Kahr Bio Australia Pty Ltd
2026-01-16 – 2027-04-30 · Colorectal Cancer
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (3)
Advanced Metastatic Colorectal Cancer
NCT07502014 · Huazhong University of Science and Technology
2026-05-01 – 2029-12-31 · Metastatic Colorectal Cancer (CRC), mCRC
What this study did
NCT05511051 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-02-01 – 2024-12-31 · Colorectal Cancer
What this study did
Colorectal Cancer
NCT07003022 · Fudan University
2025-06-01 – 2028-05-01 · Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
What this study did
Early phase / not applicable (1)
Advanced Metastatic Colorectal Cancer
NCT06551207 · Liu Huang
2024-08-20 – 2027-12-30 · Metastatic Colorectal Cancer
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fruquintinib (Fruzaqla / Elunate): this drugApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(55 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fruzaqla / Elunate (Fruquintinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
December 2026 (8)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07229872 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CancerNot yet recruiting
Est. primary completion 2026-12-15 · NCT06115733 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12-28 · NCT05954429 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06356597 · CT.gov ↗
What to watch
Phase 1Colon Cancer, Metastatic Colon CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05848739 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT05867420 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05747716 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT07257653 · CT.gov ↗
What to watch
2027 (28)
January 2027 (2)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-01 · NCT07011576 · CT.gov ↗
What to watch
Phase 4Colorectal CancerNot yet recruiting
Est. primary completion 2027-01-31 · NCT07446465 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-03-01 · NCT07510932 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-03-21 · NCT06255379 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Gastric Adenocarcinoma, Esophagogastric Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-19 · NCT07658872 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2027-06-01 · NCT07920224 · CT.gov ↗
What to watch
Phase 1/2Advanced/Metastatic Solid TumorsRecruiting
Est. primary completion 2027-06-30 · NCT05405595 · CT.gov ↗
What to watch
Phase 2Platinum Resistant Ovarian CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06973421 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07591597 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07-06 · NCT07051785 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07-28 · NCT07515820 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2027-08 · NCT07483684 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07353268 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07689292 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Rectal Neoplasms, Rectal Cancer, AdenocarcinomaRecruiting
Est. primary completion 2027-09-11 · NCT07888309 · CT.gov ↗
What to watch
October 2027 (4)
Phase 4Colorectal CancerRecruiting
Est. primary completion 2027-10-04 · NCT06562543 · CT.gov ↗
What to watch
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2027-10-15 · NCT07170982 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-10-22 · NCT05831891 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-10-30 · NCT07261709 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07621159 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Adenocarcinoma MetastaticRecruiting
Est. primary completion 2027-11-30 · NCT07392346 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT07384377 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-12-01 · NCT07136077 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-12-15 · NCT07622550 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-30 · NCT07896096 · CT.gov ↗
What to watch
Early phase / not applicableGastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT07552402 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT07488533 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT06992258 · CT.gov ↗
What to watch
2028 (11)
February 2028 (1)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-02-28 · NCT07150403 · CT.gov ↗
What to watch
March 2028 (2)
Phase 1/2Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor, Tislelizumab, GEJ AdenocarcinomaNot yet recruiting
Est. primary completion 2028-03-30 · NCT06871527 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy, Fruquintinib, PD-1Not yet recruiting
Est. primary completion 2028-03-31 · NCT06888037 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-04-17 · NCT07130903 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CancerNot yet recruiting
Est. primary completion 2028-04-27 · NCT06985316 · CT.gov ↗
What to watch
October 2028 (3)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-10-01 · NCT07724223 · CT.gov ↗
What to watch
Phase 2Stomach Neoplasms, Gastric CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07819019 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07904130 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-12 · NCT07042685 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2028-12-30 · NCT06980532 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07362836 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-01-08 · NCT06584032 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2029-04-28 · NCT07885384 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT06856837 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07286695 · CT.gov ↗
What to watch
2030 (3)
September 2030 (1)
Phase 1/2Metastatic Colorectal CarcinomaRecruiting
Est. primary completion 2030-09-04 · NCT07791758 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Metastatic Oesogastric AdenocarcinomaRecruiting
Est. primary completion 2030-11-30 · NCT07270991 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-30 · NCT07904156 · CT.gov ↗
What to watch
2031 (1)
March 2031 (1)
Early phase / not applicableColorectal CancerRecruiting
Est. primary completion 2031-03-01 · NCT07124858 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 May 2026ApprovalChina approval of ELUNATE plus sintilimab in renal cell carcinoma
China, NMPA · HUTCHMED and Innovent · Source ↗
5 June 2025Filing acceptedNMPA accepts the NDA for fruquintinib plus sintilimab in renal cell carcinoma
CN, NMPA · HUTCHMED and Innovent Biologics · Source ↗